Results presented at DDW detail the association between ALT, Fibroscan CAP, Fibroscan VCTE, and histological response to resmetirom in patients enrolled in MAESTRO-NASH.
In this Q&A, Levy discusses the current treatment landscape for PBC and what clinical trial data suggest about seladelpar’s potential for these patients.
Interim results from the open-label, phase 3 study show seladelpar demonstrated clinically meaningful improvements in markers of cholestasis and liver injury.